Bioporto: AKI adult study - insights
Yesterday before market closed, Bioporto came out with an announcement about the upcoming USA ICU Adult AKI Clinical Study.
The company appointed Dr. Andrew Allegretti, MD, MSC of Massachusetts General Hospital as the national Principal Investigator (PI) for their upcoming USA clinical study of Acute Kidney Injury (AKI) in adult patients which comprises an initial cut-off and a subsequent validation study. His research has focused on Acute Kidney Injury in the ICU including specialty populations, chronic kidney diseases and cirrhosis/hepatorenal syndrome.
Secondly Bioporto has appointed Propharma as its CRO(Clinical Research Organization) based on their experience with IVDR projects and compatibility with BioPorto’s goals.
Read full announcement here: Bioporto AKI
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 8:30 AM 11-10-2024.
Login required
This content is only available for logged in users
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read more on company page